Physician profile
Arthur E Williams
NPI 1760591788
$9,011.28
in general payments reported to CMS, 2019-2025
35 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $539 · 2021: $1,001 · 2022: $3,142 · 2023: $950 · 2024: $1,150 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,264.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $2,238.04 | 2022-2024 | Veozah |
| Novo Nordisk INC | $1,138.57 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $721.40 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $520.39 | 2022 | |
| Amgen INC. | $518.76 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $485.44 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $441.83 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $402.34 | 2020-2021 | |
| Pfizer INC. | $345.93 | 2020-2025 | |
| Lilly USA, LLC | $335.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $259.30 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $198.61 | 2019-2025 | Spravato |
| Merck Sharp & Dohme LLC | $198.59 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $166.17 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.49 | 2020-2025 | Jardiance, Tradjenta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $160.48 | 2025 | Inspire |
| Ethicon US, LLC | $124.28 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $85.28 | 2022-2025 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $72.92 | 2023-2024 | Rexulti, Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $60.80 | 2020-2022 | |
| Ibsa Pharma INC. | $53.86 | 2021-2023 | Tirosint, Licart |
| Exact Sciences Corporation | $48.14 | 2023-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $41.50 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $39.33 | 2024-2025 | Unithroid |
| Neurocrine Biosciences, INC. | $28.09 | 2022 | |
| Boston Scientific Corporation | $20.34 | 2022 | |
| Eisai INC. | $19.43 | 2021 | |
| Sumitomo Pharma America, INC. | $18.84 | 2025 | Gemtesa |
| Dexcom, INC. | $17.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.08 | 2024 | Voquezna |
| Medtronic, INC. | $16.51 | 2023 | Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $15.46 | 2021 | |
| Esperion Therapeutics, INC. | $14.61 | 2020 | |
| Allergan, INC. | $13.94 | 2020 | |
| Genentech USA, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.